Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

被引:35
|
作者
De Wolfe, T. J. [1 ,2 ]
Eggers, S. [3 ]
Barker, A. K. [3 ]
Kates, A. E. [2 ,4 ]
Dill-McFarland, K. A. [5 ]
Suen, G. [5 ]
Safdar, N. [2 ,4 ]
机构
[1] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15260 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Infect Dis, Madison, WI 53706 USA
[3] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA
[4] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA
[5] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA
来源
PLOS ONE | 2018年 / 13卷 / 09期
基金
美国国家卫生研究院; 美国食品与农业研究所;
关键词
FECAL MICROBIOTA; SEQUENCE DATA; RESISTANCE; KEGG;
D O I
10.1371/journal.pone.0204253
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10(10) CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile Infection
    Bassis, Christine M.
    Theriot, Casey M.
    Young, Vincent B.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) : 2767 - 2774
  • [42] Antibiotic treatment of Clostridium difficile infection in children – a challenge in pediatric practice
    Gabriela Leşanu
    Cristina Becheanu
    Raluca Maria Vlad
    Daniela Lemeni
    Ioana Sabina Macovei
    Daniela Păcurar
    Mirela Stocklosa
    Irina Andronie
    Alexandra Moraru
    BMC Infectious Diseases, 14 (Suppl 7)
  • [43] Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
    Venugopal, Anilrudh A.
    Johnson, Stuart
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (04) : 568 - 574
  • [44] Non-antibiotic strategies for the prevention/treatment of Clostridium difficile infection
    KuoLee, Rhonda
    Chen, Wangxue
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (12) : 1395 - 1403
  • [45] Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection
    Zycinska, K.
    Chmielewska, M.
    Lenartowicz, B.
    Hadzik-Blaszczyk, M.
    Cieplak, M.
    Kur, Z.
    Krupa, R.
    Wardyn, K. A.
    ADVANCEMENTS IN CLINICAL RESEARCH, 2016, 952 : 59 - 64
  • [46] New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile
    Johnson, Alan P.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (10) : 1389 - 1399
  • [47] Commentary: Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome
    Anonye, Blessing O.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2018, 8
  • [48] Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
    Youngster, Ilan
    Mahabamunuge, Jasmin
    Systrom, Hannah K.
    Sauk, Jenny
    Khalili, Hamed
    Levin, Joanne
    Kaplan, Jess L.
    Hohmann, Elizabeth L.
    BMC MEDICINE, 2016, 14
  • [49] Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
    Ilan Youngster
    Jasmin Mahabamunuge
    Hannah K. Systrom
    Jenny Sauk
    Hamed Khalili
    Joanne Levin
    Jess L. Kaplan
    Elizabeth L. Hohmann
    BMC Medicine, 14
  • [50] Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update
    Holleran, G.
    Scaldaferri, F.
    Ianiro, G.
    Lopetuso, L.
    Mc Namara, D.
    Mele, M. C.
    Gasbarrini, A.
    Cammarota, G.
    DRUGS OF TODAY, 2018, 54 (02) : 123 - 136